{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"The number of participants who test positive for the antibody titer against hepatitis B surface antigen (HbSAg).","groups":[{"description":"Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd or placebo for 2 weeks.\n\nLenalidomide: Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd or placebo for 2 weeks.","id":"OG000","title":"Lenalidomide"},{"description":"Placebo will be administered for 7 days prior to and 7 days after the vaccine.\n\nPlacebo: Placebo will be administered for 7 days prior to and 7 days after the vaccine.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 weeks","title":"Positive for Hepatitis B Surface Antigen","type":"PRIMARY","unitOfMeasure":"participants"}